Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Patients participating in trials or considering future access should be advised to report any persistent or severe abdominal pain (which may indicate pancreatitis or gallbladder disease), unexplained changes in heart rate, or other concerning symptoms promptly to their clinical team
Several sessions may be required
Boston, MA Frequently asked questions In the SURMOUNT-1 trial published in The New England Journal of Medicine (Jastreboff et al., 2022), participants on weekly tirzepatide 15 mg lost an average of 20.9% of body weight at 72 weeks versus 3.1% on placebo
More significant weight loss usually becomes clear around 12 weeks into treatment
In a 24-week study of 206 overweight patients who were randomized to continue on olanzapine, quetiapine, or risperidone or to switch to aripiprazole, patients who switched to aripiprazole experienced significantly greater weight reduction (3.7 kg) compared to patients who continued on their previous medications (0.7 kg) (Stroup TS et al, Am J Psychiatry 2011;168(9):947956)
